Nurix Therapeutics, Inc. (NRIX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $246.96M | +124.5% |
| 2024 | $110.00M | +101.4% |
| 2023 | $54.63M | -15.3% |
| 2022 | $64.47M | -19.9% |
| 2021 | $80.51M | -32.5% |
| 2020 | $119.36M | +242.8% |
| 2019 | $34.82M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $246.96M | +124.5% |
| 2024 | $110.00M | +101.4% |
| 2023 | $54.63M | -15.3% |
| 2022 | $64.47M | -19.9% |
| 2021 | $80.51M | -32.5% |
| 2020 | $119.36M | +242.8% |
| 2019 | $34.82M | — |